- SME status offers regulatory guidance and engagement in dialogue with EMA
- NeuroSense to open an EU office in Ulm, Germany
- Company plans to enroll patients at multiple sites across Europe in its planned Phase 3 pivotal ALS study of PrimeC
© NeuroSense Therapeutics 2021 All Rights Reserved | Site by: Webnoise | Privacy Policy | Terms | Accessibility